Introduction
Human African trypanosomiasis (sleepi i ing sickness) caused by the parasite Trypanosoma brucei gambiense is eni i demic in the Republic of the Congo. The disease is transmitted by the tsetse fly (Glossina genus) and manifests itself in two stages. The early stage (stage 1) occurs shortly after initial infection and can present as a haemolymphatic illness with fever, headaches, lymphadenopathy, and organomegaly. The late stage (stage 2) presents several months or even years after infection and is characterized by central nervous system involvement. The disease is fatal if untreated.
The early and late stages of sleeping sickness are differentiated by visualizai i tion of the parasite in cerebrospinal fluid (CSF) or the proxy indicator of white cell count in CSF. Treatment varies accordi i ing to stage. Pentamidine is currently the Research standard recommended treatment for the early stage of the disease. This drug is a waterisoluble compound given at a dose of 4 mg/kg once daily for 7 days either intramuscularly or by slow intrai i venous injection. Maximum plasma coni i centrations are attained within 1 hour of an intramuscular injection, but the drug is largely bound to plasma proteins and has a longilasting action with a slow rate of excretion. 1 Importantly, only very low concentrations of the drug are achieved in CSF, making it unsuitable for use in confirmed stage 2 cases. In September 2002, the MSF proi i grammes, in accordance with a recomi i mendation by the PNLTHA, increased the threshold separating stage 1 and 2 cases from 5 cells/mm³ to 10 cells/mm³. This change was accompanied by a fori i mal revision to the PNLTHA protocol in 2003. We did a retrospective analysis in a cohort of stage 1 patients treated for human African trypanosomiasis caused by T.b. gambiense in the Republic of the Congo. We aimed to assess whether the use of a higher CSF white cell count threshold increased the risk of relapse.
Methods
Patients were originally enrolled through passive case detection at fixed sites, as well as by active case detection by mobile teams systematically screening villages. The national protocol of the PNLTHA guided diagnosis and treatment. Diagnosis ( Fig. 1 ) involved screeni i ing (card agglutination trypanosomiasis test (CATT) with whole blood), confiri i mation (visualization of the parasite in blood or lymph, or a positive result with CATT dilution of 1 in 8), and staging (parasite found in CSF or CSF white cell count).
We analysed risk factors for treati i ment failure during the first year of followiup using Cox proportional hazards regression. Patients were ini i cluded in the analysis if they had a stage 1 diagnosis, were treated with pentamidine (4mg/kg by intramuscular (IM) injeci i tion once daily for 7 days), admitted on or after September 2002 (the month when the stage 1 to stage 2 white cell count threshold was raised), and eligible for 1 year of follow up. Patients were excluded if they had not attended at least one followiup visit or if baseline variables such as age, sex, parasitological findings and treatment outcome were not in their records.
We restricted our analysis to the first year of followiup, since followiup rates were unacceptably low for longer periods. We took any visit from month 10 (day 304) to month 14 (day 425) after discharge as the 1iyear followiup visit. We defined failure as death attributable to any cause after discharge, recurrence of parasites in any body fluid, CSF white cell count > 50 cells/mm³ and at least doubled from the previous measurement, or white cell count 11-49 cells/mm³ with either a significant increase from the previous measurement or with sympi i toms suggestive of sleeping sickness. [3] [4] [5] Potential risk factors (treatment ceni i tre, sex, age, screening mode, technique on which parasitological confirmation was based (i.e. visualization of parasite or serological alone), CSF white cell count) and confounders (period during which the patient was admitted) were entered in the multivariate model if associated with the outcome at the P < 0.20 level in a univariate analysis. We forced semester of admission into the final model since pentamidine relapse rates varied over the duration of the project (data not shown). We also tested for interactions between covariates and verified the proportionali i ity assumption.
Data were entered at programme locations into either an Excel database (Gamboma) or YoTryps (Nkayi and Mossaka), a Microsoft Accessibased software designed for human African trypanosomiasis programmes. Data were analysed with Stata version 8.0 (Stata Corp, College Station, Texas, USA).
Ethical approval
The study was a retrospective analysis on Médecins Sans Frontières' operational medical work in the Republic of the Congo. Approval for data exportation, analysis and reporting was obtained from the PNLTHA of the Republic of the Congo. The data sets extracted and used for analysis were anonymized through removal of all patients' names, separation into a new dataset, and analysis by a statistii i cian unconnected with the programmes.
Results
Between April 2001 and March 2005, 1986 patients were diagnosed with primary stage 1 human African trypanoi i somiasis. Criteria for selection of the cohort retained for analysis is shown in Fig. 2 . Of 692 patients discharged alive after treatment with pentamidine, 454 (66%) and 371 (54%) attended followi up at 6 months (± 2 months) and one year (± 2 months), respectively. Overall, 652 patients (94%) attended at least one followiup visit and were included in the multivariate analysis. Table 1 shows their baseline characteristics.
Patients not attending at 1iyear followiup differed significantly from those who did attend in the semester of admission: 159 of 228 patients (70%) admitted in September 2002 to March 2003 were seen, compared with 212 of 424 (50%) later; P < 0.001. Groups did not differ with respect to any other basei i line characteristics.
There were 33 treatment failures (5% of 652 eligible for analysis). Age, sex, mode of screening and technique of diagnosis (parasitological or serological) did not affect risk of failure ( Table 1) defaulters in the two exposure groups were otherwise similar.
Patients treated with pentamidine with a raised white cell count (6-10 cells/mm³) had a significantly higher risk of failure (adjusted hazard ratio 3.27; P = 0.002) than did those with a white cell count of 0-5 cells/mm³ ( Table 1 
Discussion
Our results show that the risk of treati i ment failure in patients with a CSF white cell count of 6-10 cells/mm³ is three times higher than in those with a count of 0-5 cells/mm³. This difference may be because some of these patients had late stage or stage 2 disease for which pentamidine treatment is ineffective.
Attempts have been made to use pentamidine to treat patients with a mild elevation of CSF white cell count. 6 Doua et al. 7 in Côte d'Ivoire, for example, showed that pentamidine could be effeci i tive in "intermediate" cases with a CSF white cell count between 6 cells/mm³ and 20 cells/mm³. However, Lejon et al. 8 in Uganda noted a higher risk of relapse for these patients treated with pentamidine 8 and went on to recommend a value of 10 cells/mm³ as a more appropriate cut off. Ruiz et al. 9 indeed found that a CSF white cell count of 6-10 cells/mm³ was not associated with a higher risk of relapse in patients treated with pentamidine. 9 Our results somewhat contradict outcomes from these studies and indicate that a lower threshold of 5 cells/mm³ may be advisable in the Republic of the Congo.
A CSF white cell count cutioff of 10 cells/mm³ to differentiate stage 1 and 2 cases is a feature of the national diagnostic protocol of the PNLTHA. Many protocols use a cutioff point of 5 cells/mm³. The reason for adopting a high threshold is because melarsoprol, which is highly toxic, was initially used for the treatment of stage 2 cases. This higher threshold seems justified in view of the fact that if the lower threshold of 5 cells/mm³ had been used, an addii i tional 84 patients (in the analysed group) would have been treated with potentially toxic stage 2 medication. Since about 5% of all patients treated with melari i soprol die from severe adverse events, we calculate that treatment of these 84 extra patients with melarsoprol would have resulted in 4 additional deaths to prevent 10 relapses. However, we feel that where an alteri i native to melarsoprol, such as eflornithine is available, use of a higher threshold is not justified. 10 In our programme in the Republic of the Congo we also found a relatively low case fatality rate of 1.7% (n = 5) among 288 patients treated with eflornithine. Furthermore, the idea that one can have a positive risk-benefit with a higher CSF white cell count is based on the assumption that all patients can be followed up and any extra relapses can be retreated. In our programme, dei i spite additional resources not normally available to the PNLTHA, only 54% of patients attended followiup at 1 year. In areas where good followiup rates can not be guaranteed, additional deaths in the community may occur in patients who relapse or who are lost or unable to attend followiup.
Overall, the treatment failure rate (5%) in our programme was accepti i able and similar to levels noted in other studies. 6, 11, 12 A high proportion (62%) of patients entered in the analysis of relapse risk were diagnosed serologically, in the absence of visualized parasites. This low rate of parasite detection may be related to poor laboratory performance. As such, the treatment of serological cases with a CATT end titre > 1/8 has been proposed as a control strategy in areas with a high prevalence of sleeping sickness. 13 Howi i ever, many serological cases may not be true cases at all and positive results may be the result of, for example, presumed cases having been treated several years ago. There is evidence of immunity foli i lowing T.b. gambiense infection and it is also known that results of the CATT may remain positive for some time. 14, 15 Furthermore, the positive predictive value of the CATT dilutions is uni i known and may vary over the length of a control programme. Perhaps a higher threshold of even 1/16 or 1/32 should be considered especially when the overall prevalence of the disease is moderate to low. Our results should be interpreted with some caution since they are dei i rived from a retrospective analysis, and are not from a randomized study but from a fieldibased medical intervention. Additionally, our data were insufficient to analyse outcomes beyond 1 year of followiup; patients can relapse up to 3 years after initial treatment.
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Conclusion
Overall, pentamidine was safe and well tolerated. However, a CSF white cell count of 10 cells/mm³ as the threshold between stage 1 and 2 cases seems to be associated with a higher risk of relapse. Therefore, we recommended that stage 1 should be defined by a CSF white cell count of 0-5 cells/mm³ (with absence of trypanosomes in the CSF) and that a count of 6 cells/mm³ and greater should be treated as a stage 2 case, especially if the alternative stage 2 drug eflornithine is available and can be safely adminisi i pacientes aptos para nuestro análisis fueron tratados con pentamidina. Todos sobrevivieron y recibieron el alta. La tasa de recaídas fue del 5% (n=33). El único factor de riesgo conocido fue un recuento de leucocitos en LCR de 6-10 células/mm³ en lugar de 0-5 células/mm 3 (razón de riesgos instantáneos ajustada = 3,27 (intervalo de confianza del 95% = 1,52-7,01); P = 0,002). Conclusiones La cifra de 5 leucocitos/mm³ en el LCR es más segura que 10 leucocitos/mm³ como umbral para determinar la fase 2 de la TAH y reducir el riesgo de recaída. 
